文献速递间质性肺疾病

靶向TAM受体改善特发性肺纤维化纤维化机制

Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

研究探讨靶向Gas6/TAM受体通路是否抑制特发性肺纤维化(IPF)成纤维细胞活化与肺纤维化。在IPF肺组织和成纤维细胞中Gas6、Axl、Tyro3表达升高,小分子TAM抑制剂R428较其他靶向药物更有效抑制IPF成纤维细胞合成、迁移和增殖,并在博来霉素及人源化SCID/Bg小鼠模型中减轻肺纤维化。提示靶向该通路可能是IPF抗纤维化策略。

要点

  • IPF肺组织及成纤维细胞中Gas6、Axl、Tyro3表达升高
  • 小分子TAM抑制剂R428较抗体更有效抑制IPF成纤维细胞活化
  • R428在博来霉素及人源化SCID/Bg小鼠中减轻肺纤维化

核心结论

  • Gas6/TAM受体活性参与IPF肺成纤维细胞活化,靶向该通路可能是有效抗纤维化策略。

研究设计与样本

  • 采用定量基因组、蛋白质组和功能分析检测正常与IPF肺组织及成纤维细胞中Gas6/TAM受体表达与活化。
  • 在博来霉素诱导肺纤维化及静脉注射原代IPF成纤维细胞后发生肺纤维化的SCID/Bg小鼠中评估该通路促纤维化作用。

主要发现

  • 与正常肺样本和成纤维细胞相比,Gas6、Axl和Tyro3在快速进展和缓慢进展IPF中均升高。
  • 用针对Gas6或Axl的特异性抗体或小分子TAM抑制剂靶向该通路,体外和体内研究均提示小分子介导的靶向方法更有效。
  • TAM受体抑制剂R428(BGB324)较其他Gas6/TAM受体靶向药物显著抑制IPF成纤维细胞的合成、迁移和增殖特性。
  • Gas6表达缺失减轻博来霉素诱导的肺纤维化反应,R428治疗抑制人源化SCID/Bg小鼠的肺纤维化。

临床怎么用

  • 靶向Gas6/TAM受体通路可能成为IPF抗纤维化治疗方向,小分子TAM抑制剂R428在实验模型中显示抑制作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Idiopathic pulmonary fibrosis (IPF) is characterized by aberrant lung remodeling, which progressively abolishes lung function in an RTK (receptor tyrosine kinase)-dependent manner. Gas6 (growth arrest-specific 6) ligand, Tyro3 (TYRO3 protein tyrosine kinase 3), and Axl (anexelekto) RTK expression and activity are increased in IPF. OBJECTIVES: To determine if targeting these RTK pathways would inhibit fibroblast activation and the development of pulmonary fibrosis. METHODS: Quantitative genomic, proteomic, and functional analyses were used to determine Gas6/TAM (Tyro3, Axl, and Mertk [MER proto-oncogene, tyrosine kinase]) RTK expression and activation in tissues and fibroblasts from normal and IPF lungs. The profibrotic impact of these RTK pathways were also examined in bleomycin-induced pulmonary fibrosis and in SCID/Bg mice that developed pulmonary fibrosis after the intravenous administration of primary IPF fibroblasts. MEASUREMENTS AND MAIN RESULTS: Gas6, Axl, and Tyro3 were increased in both rapidly and slowly progressive IPF compared with normal lung samples and fibroblasts. Targeting these pathways with either specific antibodies directed at Gas6 or Axl, or with small-molecule TAM inhibitors indicated that the small molecule-mediated targeting approach was more efficacious in both in vitro and in vivo studies. Specifically, the TAM receptor inhibitor R428 (also known as BGB324) significantly inhibited the synthetic, migratory, and proliferative properties of IPF fibroblasts compared with the other Gas6/TAM receptor targeting agents. Finally, loss of Gas6 expression decreased lung fibrotic responses to bleomycin and treatment with R428 inhibited pulmonary fibrosis in humanized SCID/Bg mice. CONCLUSIONS: Gas6/TAM receptor activity contributes to the activation of pulmonary fibroblasts in IPF, suggesting that targeting this RTK pathway might be an effective antifibrotic strategy in this disease.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Espindola MS, Habiel DM, Narayanan R, et al. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2018. PMID: 29634284. doi:10.1164/rccm.201707-1519OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。